Pfizer had previously said that both etrasimod trials were successful, but did not disclose the actual data at the time.
We believe that we have obtained one that is really one of the best that we are going to find, indicated the pharmacist. Photo: Shutterstock.
Almost a third of patients with ulcerous colitis who received an experimental drug from Pfizer Inc. in a clinical trial and were in remission following a year of treatment, the drugmaker said in a statement.
the drug, etrasimod, was the key active that Pfizer reported as successful in this clinical trial. The ulcerous colitis (UC) is an inflammatory bowel disease. It affects around 3.8 million people in North America and Europe, according to the company, which plans to seek US approval for etrasimod to treat UC in the second half of this year.
In their 52-week, 409-patient study, 32.1% of those who received etrasimod were in clinical remission following one year, compared to 6.7% of those who received a placebo.
Twelve weeks following that trial, clinical remission was 27% among recipients of etrasimod versus 7.4% in the placebo group.
In a separate 12-week study, Pfizer said clinical remission was achieved in 24.8% of patients receiving etrasimod compared to 15.2% of patients who received a placebo.
Etrasimod It belongs to a class of medications called sphingosine 1-phosphate (S1P) receptor modulators. “We’ve always been interested in S1P,” Michael Corbo, Pfizer’s director of immunology and inflammation development, said in an interview. “We think we’ve got one that’s really one of the best we’re going to find.”
Pfizer had previously said that both trials with etrasimod they were successful, but did not disclose the actual data at the time.
consulted source here.
